<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01101906</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-906-206</org_study_id>
    <secondary_id>2010-018739-17</secondary_id>
    <nct_id>NCT01101906</nct_id>
  </id_info>
  <brief_title>A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC</brief_title>
  <official_title>A Randomized, Placebo-controlled, Double-blinded Phase 2 Study of Second-line Treatment With OSI-906 in Patients With Advanced Hepatocellular Carcinoma (HCC) After Failure of First-line Treatment With Sorafenib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, double-blind phase 2 study of OSI-906 or placebo at
      a continuous 150 mg twice daily (BID) dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adult patients with advanced HCC previously treated with sorafenib will be randomized 2:1 to
      receive either single agent OSI-906 or placebo
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decided not to pursue the development of this drug in this patient population at this
    time
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>20 months</time_frame>
    <description>Time from randomization to radiological disease progression based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>23 months</time_frame>
    <description>Date of randomization until the documented date of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>23 months</time_frame>
    <description>Time from randomization to radiological disease progression based on RECIST version 1.1 assessed by investigator or death due to any cause whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (including clinical progression) (TTPc)</measure>
    <time_frame>23 months</time_frame>
    <description>Time from randomization to progression (either radiological disease progression based on RECIST version 1.1 or symptomatic clinical progression as assessed by investigator)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>23 months</time_frame>
    <description>Proportion of patients with a best overall response of complete response (CR), partial response (PR), or stable disease based on RECIST version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>23 months</time_frame>
    <description>Proportion of patients with a best overall response of CR or PR based on RECIST version 1.1 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression in patients with hepatitis B virus (HBV) and/or hepatitis C virus (HVC)</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate in patients with HBV and/or HCV</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed via physical examination, vital signs, clinical laboratory tests, electrocardiograms (ECGs) and recording adverse events</measure>
    <time_frame>23 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Advanced Hepatocellular Carcinoma (HCC)</condition>
  <arm_group>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSI-906</intervention_name>
    <description>OSI-906 administered orally</description>
    <arm_group_label>Arm A: OSI-906</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo administered orally</description>
    <arm_group_label>Arm B: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed diagnosis of advanced HCC. Clinical diagnosis by American
             Association for the Study of Liver Diseases (AASLD) criteria in cirrhotic patients is
             acceptable. For patients without cirrhosis histological confirmation is mandatory

          -  Patients must have received prior systemic treatment for advanced HCC with sorafenib
             and had confirmed disease progression or had discontinued sorafenib due to a drug
             related toxicity

          -  Patient has received their last dose of sorafenib at least 14 days prior to
             randomization

          -  Patient has recovered from sorafenib or investigational agent related toxicity to ≤
             grade 2

          -  Measurable disease according to RECIST (version 1.1)

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 - 1

          -  Child-Pugh Status A or B(7)

          -  Barcelona Clinic Liver Cancer (BCLC) stage B/C

          -  Previous local therapy (eg, surgery, radiation therapy, hepatic arterial therapy,
             chemoembolization, radiofrequency ablation, percutaneous ethanol injection, or
             cryoablation) is permitted if ≥ 21 days before randomization

          -  Fasting glucose ≤ 150 mg/dL (8.3 mmol/L). Concurrent use of non-insulinotropic oral
             antihyperglycemic therapy is permitted if the dose has been stable for ≥ 4 weeks at
             the time of randomization

          -  Following laboratory parameters (determined by laboratory):

               -  Platelets ≥ 60 x 10^9/L

               -  Hemoglobin ≥ 8.5 g/dL

               -  Absolute neutraphil count (ANC) ≥ 1.5 x 10^9/L

               -  Potassium within normal limits (supplementation may be used)

               -  Partial thrombopastin time (PTT) ≤ 2.3 x Upper Limit of Normal (ULN)

               -  Magnesium within normal limits (supplementation may be used)

               -  Calcium within normal limits (supplementation may be used)

          -  Adequate organ function (for a HCC population):

               -  Liver function test (LFT) ≤ 5 x ULN

               -  Albumin ≥ 2.8 g/dL

               -  Total bilirubin ≤ 2.8 mg/dL

               -  Creatinine ≤ 1.5 x ULN

               -  International normalized ratio (INR) ≤ 2.3

          -  Estimated life expectancy ≥ 12 weeks based on an investigator assessment of recent
             changes in laboratory values, performance status, and other clinical criteria

          -  Patients, both males and females, with reproductive potential (ie, menopausal for less
             than 1 year and not surgically sterilized) must agree to practice effective
             contraceptive measures throughout the study. Women of childbearing potential must
             provide a negative pregnancy test (serum or urine) within 14 days prior to
             randomization

          -  Patients must provide written informed consent to participate in the study

          -  Prior radiation therapy is permitted provided patients have recovered from the acute,
             toxic effects of radiotherapy prior to randomization. A minimum of 21 days must have
             elapsed between the end of radiotherapy and randomization; and

          -  Prior surgery is permitted provided that the surgery was done ≤ 28 days prior to
             randomization and adequate wound healing has occurred prior to randomization

        Exclusion Criteria:

          -  Child-Pugh B (8 - 9) or C

          -  Patients who are candidates for potentially curative intervention (ie, surgical
             resection or transplantation)

          -  Type 1 diabetes mellitus or Type 2 diabetes mellitus currently requiring
             insulinotropic or insulin therapy

          -  Prior insulin-like growth factor - 1 receptor (IGF-1R) therapy

          -  Patients requiring interferon

          -  Patients with uncontrolled symptomatic ascites

          -  Prior investigational agent within 21 days prior to randomization

          -  History of poorly controlled gastrointestinal disorders that could affect the
             absorption of study drug (eg, Crohn's disease, ulcerative colitis, etc)

          -  History of organ allograft including liver transplant

          -  Malignancy other than HCC within the past 3 years:

               -  Exceptions: resected basal cell or squamous cell carcinoma of the skin, cured in
                  situ cervical carcinoma, cured ductal carcinoma in situ of the breast, and/or
                  cured superficial bladder cancer

          -  History (within last 6 months) of significant cardiovascular disease unless the
             disease is well-controlled. Significant cardiac disease includes second/third degree
             heart block; clinically significant ischemic heart disease; superior vena cava (SVC)
             syndrome; poorly controlled hypertension; congestive heart failure of New York Heart
             Association (NYHA) Class II or worse (slight limitation of physical activity;
             comfortable at rest, but ordinary physical activity results in fatigue, palpitation,
             or dyspnea)

          -  History of arrhythmia (multifocal premature ventricular contractions [PVCs], bigeminy,
             trigeminy, ventricular tachycardia, or uncontrolled atrial fibrillation) that is
             symptomatic or requires treatment (≥ grade 3), left bundle branch block (LBBB), or
             asymptomatic sustained ventricular tachycardia are not allowed. Patients with atrial
             fibrillation controlled by medication are not excluded

          -  QTcF interval at screening ≥ 450 msec

          -  Use of drugs that have a known risk of causing Torsades de Pointes (TdP) ('Torsades
             List' on www.azcert.org/medical-pros/drug-lists/by category.cfm)are prohibited within
             14 days prior to randomization

          -  Use of the potent CYP1A2 inhibitors ciprofloxacin and fluvoxamine. Other less potent
             CYP1A2 inhibitors/inducers are not excluded

          -  History of cerebrovascular accident (CVA) within 6 months prior to randomization or
             that resulted in ongoing neurologic instability

          -  Active infection or serious underlying medical condition (including any type of active
             seizure disorder within 12 months prior to randomization) that would impair the
             ability of the patient to receive study drug

          -  History of human immunodeficiency virus (HIV) infection or acquired immune deficiency
             syndrome (AIDS)-related illness or serious acute or chronic illness

          -  History of any psychiatric or neurologic condition that might impair the patient's
             ability to understand or to comply with the requirements of the study or to provide
             informed consent

          -  Pregnant or breast-feeding females

          -  Symptomatic brain metastases that are not stable, require steroids, are potentially
             life threatening, or that have required radiation within 28 days prior to
             randomization; and/or

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to study drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Global Development</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California - Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University Health Services Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Mason Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>52336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussells</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jean Verdier - Dervice d'Hepato-Gastroenterologie</name>
      <address>
        <city>Bondy Cedex</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Mondor</name>
      <address>
        <city>Creteil cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de la Timone</name>
      <address>
        <city>Marseille Cedex 5</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital l'Archet 2</name>
      <address>
        <city>Nice cedex 03</city>
        <zip>6202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Antoine</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Tenon</name>
      <address>
        <city>Paris cedex 12</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Gauducheau</name>
      <address>
        <city>Saint Herblain cedex</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Halle</name>
      <address>
        <city>Halle</city>
        <zip>06097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Magdeburg A.ö.R.</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione Ca' Granda Ospedale Maggiore Policlinico, Divisione di Gastroenterologia I</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Fatebenefratelli, Dipartimento Medicina Interna</name>
      <address>
        <city>Napoli</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Nazionale per lo studio e la cura dei tumori Fondazione G. Pascale-SSD Epatobiliare</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione ISMETT-Dipartimento di Epatologia e Gastroenterologia</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <zip>410-769</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-774</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins Singapore International Medical Centre</name>
      <address>
        <city>Singapore</city>
        <zip>308433</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago de Compostela</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Coruna</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic Provincial</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro Majadahonda</name>
      <address>
        <city>Madrid</city>
        <zip>28220</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Universitaria de Navarra</name>
      <address>
        <city>Pamplona</city>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Changhua Christian Hospital</name>
      <address>
        <city>Changhua</city>
        <zip>500</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40705</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Medical Foundation LinKou Branch</name>
      <address>
        <city>TaoYuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 8, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2010</study_first_posted>
  <disposition_first_submitted>December 10, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>December 10, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 12, 2012</disposition_first_posted>
  <last_update_submitted>December 10, 2012</last_update_submitted>
  <last_update_submitted_qc>December 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OSI-906</keyword>
  <keyword>HCC</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

